A146P (p.Ala146Pro) variant of KRAS (GTPase KRas)
A146P (p.Ala146Pro) in KRAS (GTPase KRas) is a missense change. Clinical records from ClinVar, EBI, and UniProt describe it as pathogenic/likely pathogenic in the context of RASopathy; Encephalocraniocutaneous lipomatosis; Autoimmune lymphoproliferative. The available variant effect predictions contribute to a CATVariant prioritization score of 0.88 / 1. The record also includes population frequency data, experimental measurements, published literature, and structural context.
A146P (p.Ala146Pro) variant details
- p.Ala146Pro
- rs121913527
- ClinGen CA16602441
- cosmic curated COSV55541
- ClinVar RCV000984134
- Pathogenic/Likely pathogenic
- RASopathy; Encephalocraniocutaneous lipomatosis; Autoimmune lymphoproliferative
- Missense
- Variant Prioritization Score for Impact Estimate 0.881
- REVEL 0.94
- ESM-1b 1.00
- AlphaMissense 1.00
- MetaLR 0.91
- MetaSVM 1.08
- CADD 29.40
- ClinVar: Pathogenic/Likely pathogenic (RASopathy; Encephalocraniocutaneous lipomatosis; Autoimmune lymp)
- EBI: Pathogenic (in OES)
- UniProt: Pathogenic (in OES)
- Most common in the Non-Finnish European population (allele frequency 1.5e-05)
- Structural context available
- KRAS activity — DMSO (standardized): score 8.64
- Cited in: Encephalocraniocutaneous Lipomatosis. (PMID 35099867)